GITNUX MARKETDATA REPORT 2024

Statistics About The Average Psa With Prostate Bone Metastasis

The average PSA level in patients with prostate cancer and bone metastasis is typically elevated above 100 ng/mL.

In this post, we will discuss key statistics related to prostate cancer bone metastasis, focusing on Prostate-specific antigen (PSA) levels and their implications for diagnosis and survival rates. With insights from recent studies published in JAMA Oncology, we will explore how PSA levels serve as strong predictors of bone metastasis and the challenges faced by individuals with advanced prostate cancer.

Statistic 1

"Men with metastatic prostate cancer had an average Prostate-specific antigen (PSA) level of 150 ng/ml at diagnosis, according to a study published in JAMA Oncology."

Sources Icon

Statistic 2

"People surviving for 5 years from their prostate cancer diagnosis, with bone metastasis, is 28%."

Sources Icon

Statistic 3

"A PSA increase of 2.0 ng/mL or higher than the PSA nadir (lowest point) is a strong predictor of bone metastasis in prostate cancer."

Sources Icon

Statistic 4

"The average bone metastasis free survival is only 40% at 5 years for those men with a PSA level greater than 20 ng/mL at diagnosis."

Sources Icon

Statistic 5

"Almost 80% of patients with metastatic castrate-resistant prostate cancer (mCRPC) have bone metastases."

Sources Icon

Statistic 6

"49% of patients with prostate cancer bone metastasis show an increase in PSA levels."

Sources Icon

Statistic 7

"85% of metastatic prostate cancer cases involve metastasis to bone."

Sources Icon

Statistic 8

"Over 90% of men with advanced prostate cancer develop bone metastases."

Sources Icon

Statistic 9

"The 10-year relative survival rate for localized prostate cancer that has spread to other parts of the body, like bones, is 28%."

Sources Icon
In conclusion, the statistics presented in the study highlight the significant impact of prostate-specific antigen levels, bone metastasis, and survival rates for men with metastatic prostate cancer. The average PSA level of 150 ng/mL at diagnosis and the strong association between PSA increase and bone metastasis underscore the importance of monitoring PSA levels in prostate cancer patients. The low survival rate of 28% at 5 years for those with bone metastasis emphasizes the need for early detection and intervention. The high prevalence of bone metastases in advanced prostate cancer cases further accentuates the challenges posed by this aggressive disease. These statistics underscore the critical role of PSA monitoring, early detection, and targeted treatment strategies in improving outcomes for men with metastatic prostate cancer.

... Before You Leave, Catch This! 🔥

Your next business insight is just a subscription away. Our newsletter The Week in Data delivers the freshest statistics and trends directly to you. Stay informed, stay ahead—subscribe now.

Sign up for our newsletter and become the navigator of tomorrow's trends. Equip your strategy with unparalleled insights!